Clinical Trials on De Novo Lipogenesis

Total 245 results

University Children's Hospital Basel
Swiss National Science Foundation; Fondation Botnar

Completed

Measurement of Lipogenic Flux by Deuterium Resolved Mass Spectrometry Via Non-invasive Breath Analysis (D2OBREATH)

De Novo Lipogenesis (DNL)

Switzerland
Novartis

Completed

Pharmacokinetic Study of AEB071 in Patients Following Liver Transplantation

de Novo Liver Transplantation

Germany, Italy, Switzerland
University Hospital, Tours
Astellas Pharma Inc

Unknown

Efficacy and Safety Study of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus(ADEQUATE) (ADEQUATE)

De Novo Transplant Disease

France
Yale University
Juvenile Diabetes Research Foundation

Terminated

Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes

Type 1 Diabetes | De Novo Lipogenesis

United States
Novartis

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

De Novo Kidney Transplant Recipients
Rigshospitalet, Denmark

Completed

Early Detection of de Novo Cancer in Liver Transplant Recipients (DETECT)

Liver Transplant Disorder | De Novo Cancer
Novartis Pharmaceuticals

Completed

Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients

De Novo Renal Transplantation

Norway
Astellas Pharma Inc

Completed

A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients

De Novo Kidney Transplantation

Belgium, France, Netherlands, Spain, Sweden, Austria, Italy, Germany, United Kingdom, Hungary, Poland, Czech Republic
Novartis

Completed

Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant Patients

De Novo Kidney Transplantation
Astellas Pharma Inc

Completed

Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients

De Novo Kidney Transplant Patients

China
Astellas Pharma Korea, Inc.

Completed

A Study to Evaluate the Effect of Advagraf Conversion From Prograf in Liver Transplant Subjects (Maple)

de Novo Liver Transplant Subjects

Korea, Republic of
Erasmus Medical Center
Hoffmann-La Roche

Completed

Fixed Dose MMF vs Concentration Controlled MMF After Renal Transplantation

De Novo Renal Transplant Recipient.

France, Spain, Taiwan, Denmark, Australia, United Kingdom, Germany, Canada, Belgium, China, Sweden, Netherlands, Austria, Brazil, Estonia, Lithuania, Norway, Poland, Venezuela
Medinol Ltd.

Completed

NIRTRAKS Post-Market Study (NIRTRAKS) (NIRTRAKS)

de Novo Stenotic Lesions in Native Coronary Arteries

United States
Biotronik AG

Completed

First in Man Trial - BIOSOLVE-I (BIOSOLVE-I)

de Novo Lesions in Native Coronary Arteries

Netherlands, Switzerland, Germany, Belgium
Biotronik AG

Completed

Long Term Safety Profile of the PRO-Kinetic ENERGY Coronary Stent System in Daily Clinical Practice (ENERGY)

De Novo and Re-stenosed Coronary Artery Lesions

Switzerland, Netherlands, Israel, Spain, Latvia, Germany, Austria, Belgium, France, Ireland
Novartis Pharmaceuticals

Completed

Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.

Kidney de Novo Transplant
Novartis

Completed

Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids. (EVIDENCE)

Renal Transplantation | de Novo Kidney Transplant Recipients

Italy
University Hospital, Tours
Astellas Pharma Inc

Unknown

Prospective Study to Measure Vascular Parameters (Ancillary Study of ADEQUATE) (ADEQUATEartère)

De Novo Transplant Disease

France
Boston Scientific Corporation

Completed

TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program (ARRIVE 2)

Cardiovascular Disease | de Novo Coronary Lesions

United States
Astellas Pharma Korea, Inc.

Completed

Study to Evaluate the Safety and Efficacy of Advagraf vs Prograf in Kidney Transplantation Patients 1 Month After the Transplantation (AdProCISE)

de Novo Kidney Transplantation

Korea, Republic of
Shenzhen People's Hospital

Not yet recruiting

Resting Full-cycle Ratio-guided Step by Step Balloon Dilation (REDUCE)

de Novo Coronary Lesions
Novartis Pharmaceuticals

Completed

Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients

de Novo Heart Failure

United States
Novartis Pharmaceuticals

Completed

Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients (Spartacus)

Pharmacokinetics Study in de Novo Kidney Transplantation

Germany
Abbott Medical Devices
Baim Institute for Clinical Research

Withdrawn

Comparative Study Of Safety And Efficacy Of The SUPERA® Nitinol Stent - Iliac Artery (I-WIN)

With de Novo or Restenotic Lesions in the Common and/or External Iliac Arteries
National Institute of Allergy and Infectious Diseases...
Clinical Trials in Organ Transplantation; Cooperative Clinical Trials in Pediatric...

Completed

Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies

Kidney Transplant | Kidney Transplant Recipient | Graft Function/Survival | de Novo HLA Antibodies Development

United States
China National Center for Cardiovascular Diseases

Recruiting

STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial (STENTLESS)

De Novo Stenosis | Drug-coated Balloon | Drug-eluting Stent

China
Medinol Ltd.

Completed

MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR) (JNIR)

de Novo or Restenosis Lesions

Japan
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Recruiting

Bail-Out Stenting and Target-vessel Failure After Drug Coated Balloon Coronary percutaneouS Angioplasty for de Novo Lesions (BOSS)

PCI | De Novo Stenosis | DCB

Italy
Novartis

Completed

Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants (MYTHOS

De Novo Renal Transplantation
PETHEMA Foundation

Recruiting

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Leukemia, Myeloid, Acute | De Novo | Age More 60yr

Spain
University Hospital, Saarland

Terminated

Efficacy of the SeQuent®Please in the Treatment of De-novo Stenoses Versus Taxus™Liberté™ (PEPCAD-DEBonly)

Coronary De-novo Stenoses

Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Heart Transplant Recipients

Patients Successfully Completing the 12-month Treatment Period of the Core Study (de Novo Heart Recipients) Who Were Interested of Being Treated With EC-MPS
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Impact on Mortality of a Strategy Including Continuous Positive Airway Pressure Plus High Flow Nasal Cannula Oxygen Therapy Versus High Flow Nasal Cannula Oxygen Therapy Alone in Patients With de Novo Acute Hypoxemic Respiratory Failure: a Prospective, Randomized Controlled Trial. (HighCPAP)

De Novo Hypoxemic Acute Respiratory Failure (hARF)
Zunyi Medical College

Recruiting

Joint Inflation With Nominal-pressure and Stability Approach in DES Optimization

Acute Coronary Syndrome | De Novo Stenosis

China
Centre Hospitalier Universitaire Dijon

Completed

Social and Prognostic Inequalities in Patients Hospitalised for Cerebrovascular Accident (CVA) in Four Contrasting French Departments (INDIA)

Symptomatic CVA (de Novo CVA)

France
Xijing Hospital

Active, not recruiting

Paclitaxel-coated Balloon for Treatment of De-novo Non-complex Coronary Artery Lesions

Coronary Artery Disease | De Novo Stenosis

China
Gesellschaft fur Medizinische Innovation - Hamatologie...

Recruiting

National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup

Newly-diagnosed APL (de Novo or Therapy-related) | Relapsed APL

Germany
Imperial College London Diabetes Centre

Unknown

Delineation of Novel Monogenic Disorders in the United Arab Emirates Population

Mendelian Disorders | Genetic Disorder | Novel Mutation | Hereditary Disorder | De Novo Mutation | Inherited Disease | Single-Gene Defects

United Arab Emirates
Merck Sharp & Dohme LLC

Terminated

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005)

DLBCL | AML Including AML de Novo and AML Secondary to MDS
Xijing Hospital

Active, not recruiting

Paclitaxel-Coated Balloon Versus Zotarolimus-Eluting Stent for Treatment of De Novo Coronary Artery Lesions (CAGE-FREEIII)

Coronary Artery Disease | Percutaneous Coronary Intervention | De Novo Stenosis

China
Novartis Pharmaceuticals

Terminated

MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive

De Novo Kidney Transplant
Genoss Co., Ltd.

Completed

Compare the Efficacy and Safety of Genoss® DCB and IN.PACT Admiral® DCB in Patients With Peripheral Artery Disease

Peripheral Artery Disease | De Novo Stenosis

Korea, Republic of
Sydney South West Area Health Service

Unknown

IVUS Controlled Stenting

Coronary Angioplasty and Stenting | Single de Novo Coronary Artery Stenoses

Australia
Nanfang Hospital of Southern Medical University

Unknown

Small Intestinal Submucosa Scaffold Combined With Adipose-derived Stem Cells to Form an Adipocyte-containing Hypodermis

Adipogenesis

China
Korea University Ansan Hospital
B. Braun Korea Co., Ltd.

Recruiting

STabilization of Atheroma By Lipid-reducing Effect of Drug-Coated Balloon (STABLE-DCB) (STABLE-DCB)

Coronary Artery Disease | De Novo Stenosis | Atherosclerotic Plaque

Korea, Republic of
Xijing Hospital

Recruiting

Intravascular Lithotripsy Versus Conventional Therapy for Severely Calcified Coronary Artery Lesions (REC-CHIPCAC)

De Novo Stenosis | Severely Calcified Coronary Stenoses

China
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...

Completed

A Phase I Study of Immunotherapy With GSC -Loaded Dendritic Cells in Patients With Recurrent Glioblastoma (DENDR-STEM)

de Novo Glioblastoma
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes

Previously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes

United States
Brendon Gurd, PhD

Completed

Examining The Effect of Blood Flow Restricted Aerobic Training on Mitochondrial Adaptations in Young Healthy Adults

Mitochondrial Biogenesis

Canada
Brendon Gurd, PhD

Unknown

Time-course of Mitochondrial Biogenic Gene and Protein Expression in Exercised Human Skeletal Muscle

Mitochondrial Biogenesis

Canada

Clinical Trials on De Novo Lipogenesis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations